Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phaseoloideside E (PE) is a novel oleanane-type triterpene saponin isolated from the seed kernels of *Entada phaseoloides* (Linn.) Merr. It has demonstrated potent cytotoxic activity against various malignant cell lines, including the Ec-109 esophageal carcinoma cell line. PE induces apoptosis through a mechanism involving the up-regulation of cellular reactive oxygen species (ROS) production, which leads to a decrease in mitochondrial membrane potential, reduction in superoxide dismutase (SOD) activity, and depletion of glutathione (GSH) content. This oxidative stress triggers the intrinsic apoptotic pathway, characterized by a reduced Bcl-2/Bax ratio and the activation of caspase-9 and caspase-3. Notably, PE appears to selectively induce cell death in transformed cells while sparing untransformed cells, suggesting its potential as a targeted therapeutic agent for esophageal carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phaseoloideside e.